Business Wire

Naomi Park from USA wins Stockholm Junior Water Prize 2023

22.8.2023 21:14:00 EEST | Business Wire | Press release

Share

Naomi Park from USA receives the prestigious Stockholm Junior Water Prize 2023 for her research on the removal of carbon dioxide and oil products from the ocean. HRH Crown Princess Victoria of Sweden presented the winner with her award during a ceremony at World Water Week in Stockholm.

The ocean absorbs nearly a third of airborne carbon dioxide emissions, and 1.3 million gallons of crude oil are spilled into oceans every year. Both issues continue to detrimentally affect marine biodiversity, and human health. In her research, Naomi Park has developed a method to simultaneously remove these contaminants.

For this, she was announced the winner of Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.

Speaking on winning the prize, Park said: “I did this project in my high school. I joined our research program as a freshman. It is just something that I wanted to do for fun. I never realized that I would get to this point. It is very much a shock right now.”

The Jury noted that “the winner is taking a troublesome waste product and using it to help solve a number of the most pressing issues we face in the modern world. By using Styrofoam and creating a ‘sponge’ that absorbs both carbon dioxide and oil products from the ocean, this student built a model and tested it – in multiple conditions, even simulating ocean waves – with impressive results.”

The winner was presented with her prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.

The Diploma of Excellence was awarded to Ayse Pelin Dedeler from Türkiye for her study on how to capture microplastics with magnetic nano-adsorbents and remove them from the water using strong magnets.

The People’s Choice Award went to Fernando de Silva Hernández and Carlos Erquizio from Mexico, completing the line-up of winners.

The Stockholm Junior Water Prize has been organized every year since 1997 by the Stockholm International Water Institute, SIWI, with Xylem as Founding Partner.

“The Stockholm Junior Water Prize is a tribute to an entire generation of motivated young people, eager to tackle the greatest challenges of our time. Their passion, ingenuity, and determination to be part of a better future is truly inspiring. It is also a stark reminder that we must all do our part, and we must do it now,” said Karin Gardes, Acting Executive Director of Stockholm International Water Institute.

Patrick Decker, Xylem’s President and CEO, added: “The next generation of water innovators is already making a difference today – as all the Stockholm Junior Water Prize participants show. I join 22,000 Xylem colleagues and our many partners around the world in honoring their big ideas and bold ambitions. We’re inspired by what’s to come and welcome them to the global movement to solve water.”

For more information: www.siwi.org/prizes.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jakob Schabus
Communications Manager
Stockholm International Water Institute
Email: jakob.schabus@siwi.org
Mobile: +46 (0) 720 50 60 39

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye